PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  04:03 2022-08-18 pm EDT
48.58 USD   -1.40%
08/17GSK Says No Payment Made After Zantac Plaintiff Drops Lawsuit
MT
08/17Moderna - Evidation Enables First of Its Kind Moderna Study to Track COVID Vaccine Response in Real Life
AQ
08/17GSK shares ease after plaintiff in first Zantac lawsuit drops case
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer Maintains Quarterly Dividend at $0.40 a Share; Payable Sept. 6 to Shareholders as of July 29

06/23/2022 | 11:36am EDT


© MT Newswires 2022
All news about PFIZER, INC.
08/17GSK Says No Payment Made After Zantac Plaintiff Drops Lawsuit
MT
08/17Moderna - Evidation Enables First of Its Kind Moderna Study to Track COVID Vaccine Resp..
AQ
08/17GSK shares ease after plaintiff in first Zantac lawsuit drops case
RE
08/17GSK Says First US Plaintiff to Drop Zantac Case
DJ
08/16Plaintiff in first Zantac lawsuit set for trial drops case
RE
08/16Ambrx Biopharma Names Kate Hermans Interim CEO
MT
08/16PFIZER : Statement from Pfizer Chairman and CEO Albert Bourla on Testing Positive for COVI..
PU
08/16Pfizer Inc. - Statement from Pfizer Chairman and CEO Albert Bourla on Testing Positive ..
AQ
08/16Digital innovations and congress coverage led to an increase in all hub users
AQ
08/15Pfizer CEO tests positive for COVID-19, has mild symptoms
AQ
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 102 B - -
Net income 2022 32 675 M - -
Net cash 2022 11 522 M - -
P/E ratio 2022 8,62x
Yield 2022 3,34%
Capitalization 273 B 273 B -
EV / Sales 2022 2,57x
EV / Sales 2023 3,25x
Nbr of Employees 79 000
Free-Float 59,0%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 48,58 $
Average target price 56,53 $
Spread / Average Target 16,4%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-17.73%276 521
JOHNSON & JOHNSON-2.04%440 598
ELI LILLY AND COMPANY14.70%301 034
ROCHE HOLDING AG-16.47%273 077
ABBVIE INC.4.46%250 080
NOVO NORDISK A/S5.17%239 447